The epidemiology and therapeutic options for the COVID-19

被引:12
作者
Li, Jingwei [1 ]
Shao, Jun [1 ]
Wang, Chengdi [1 ]
Li, Weimin [1 ]
机构
[1] Sichuan Univ, West China Hosp, West China Med Sch, Dept Resp & Crit Care Med, Chengdu 610041, Peoples R China
基金
中国国家自然科学基金;
关键词
coronavirus disease 2019; COVID-19; epidemiology; clinical features; treatment; CLINICAL CHARACTERISTICS; CORONAVIRUS; SARS-COV-2; WUHAN; TRANSMISSION; COMBINATION; TARGETS; VACCINE; BINDING; PROTEIN;
D O I
10.1093/pcmedi/pbaa017
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
An outbreak of coronavirus disease 2019 (COVID-19), a disease caused by a novel pneumonia virus, has affected over 200 countries and regions worldwide. With the increasing number of patients and deaths, WHO have declared it as a global pandemic currently, indicating a third large-scale epidemic coronavirus has appeared since the emergence of severe acute respiratory syndrome coronavirus (SARS) and Middle-East respiratory syndrome (MERS) in the twenty-first century. Considering the great harm it has caused, researchers throughout the world have been chasing to exploit the pathophysiology, characteristics, and potential remedies for COVID-19 to better battle the outbreak. Therefore, the current study revisits advances of the virology, epidemiology, clinical features, therapeutic options, and prevention of COVID-19. The features of asymptomatic carriers are also been explored.
引用
收藏
页码:71 / 84
页数:14
相关论文
共 139 条
  • [1] Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies
    Ahmed, Syed Faraz
    Quadeer, Ahmed A.
    McKay, Matthew R.
    [J]. VIRUSES-BASEL, 2020, 12 (03):
  • [2] [Anonymous], RADIOLOGY, DOI [10.5772/intechopen.80730, DOI 10.1148/radiol.2020200642, 10.1148/radiol.2020200642]
  • [3] [Anonymous], 2020, CHINA CDC WEEKLY, V2, P113, DOI [10.46234/ccdcw2020.032, DOI 10.46234/CCDCW2020.032]
  • [4] CRISPR-Cas14 is now part of the artillery for gene editing and molecular diagnostic
    Aquino-Jarquin, Guillermo
    [J]. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2019, 18 : 428 - 431
  • [5] Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State
    Arentz, Matt
    Yim, Eric
    Klaff, Lindy
    Lokhandwala, Sharukh
    Riedo, Francis X.
    Chong, Maria
    Lee, Melissa
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (16): : 1612 - 1614
  • [6] Atluri S, 2020, PAIN PHYSICIAN, V23, pE71
  • [7] Presumed Asymptomatic Carrier Transmission of COVID-19
    Bai, Yan
    Yao, Lingsheng
    Wei, Tao
    Tian, Fei
    Jin, Dong-Yan
    Chen, Lijuan
    Wang, Meiyun
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (14): : 1406 - 1407
  • [8] The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
    Bao, Linlin
    Deng, Wei
    Huang, Baoying
    Gao, Hong
    Liu, Jiangning
    Ren, Lili
    Wei, Qiang
    Yu, Pin
    Xu, Yanfeng
    Qi, Feifei
    Qu, Yajin
    Li, Fengdi
    Lv, Qi
    Wang, Wenling
    Xue, Jing
    Gong, Shuran
    Liu, Mingya
    Wang, Guanpeng
    Wang, Shunyi
    Song, Zhiqi
    Zhao, Linna
    Liu, Peipei
    Zhao, Li
    Ye, Fei
    Wang, Huijuan
    Zhou, Weimin
    Zhu, Na
    Zhen, Wei
    Yu, Haisheng
    Zhang, Xiaojuan
    Guo, Li
    Chen, Lan
    Wang, Conghui
    Wang, Ying
    Wang, Xinming
    Xiao, Yan
    Sun, Qiangming
    Liu, Hongqi
    Zhu, Fanli
    Ma, Chunxia
    Yan, Lingmei
    Yang, Mengli
    Han, Jun
    Xu, Wenbo
    Tan, Wenjie
    Peng, Xiaozhong
    Jin, Qi
    Wu, Guizhen
    Qin, Chuan
    [J]. NATURE, 2020, 583 (7818) : 830 - +
  • [9] Biontech SE, 2020, STUDY DESCRIBE SAFET
  • [10] Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality
    Bonow, Robert O.
    Fonarow, Gregg C.
    O'Gara, Patrick T.
    Yancy, Clyde W.
    [J]. JAMA CARDIOLOGY, 2020, 5 (07) : 751 - 753